Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Males of soybean cyst nematode, or H. glycines, are able reverse neurodegeneration as part of their natural life cycle.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.
Evecxia has officially named John Kaiser as its CEO and interim chairman of its board of directors, after working with the Duke spinout since March.
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
In this week's EuroBiotech Report, Pfizer, BioNTech ink $425 million deal, British biotechs reel in $247 million in VC cash and more.
Pfizer has also committed to up to $305 million in development, regulatory and commercial milestones to seal the deal.
Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.
Terumo BCT announced that David Perez will retire as president and CEO following nearly 20 years at the company.
Merck & Co. and Geisinger are in talks with health IT firms that could help take their two new EHR apps to market.